You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

Biomarin Pharmaceutical Inc. Company Profile

✉ Email this page to a colleague

« Back to Dashboard

Summary for Biomarin Pharmaceutical Inc.

Biologic Drugs for Biomarin Pharmaceutical Inc.

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Patent Expiration
Biomarin Pharmaceutical Inc. ALDURAZYME laronidase Injection 125058 2003-04-30 ⤷  Sign Up
Biomarin Pharmaceutical Inc. NAGLAZYME galsulfase Injection 125117 2005-05-31 ⤷  Sign Up
Biomarin Pharmaceutical Inc. VIMIZIM elosulfase alfa Injection 125460 2014-02-14 ⤷  Sign Up
Biomarin Pharmaceutical Inc. BRINEURA cerliponase alfa Injection 761052 2017-04-27 ⤷  Sign Up
Biomarin Pharmaceutical Inc. PALYNZIQ pegvaliase-pqpz Injection 761079 2018-05-24 ⤷  Sign Up
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.